Research programme: MC 305904 anti-fungals - Essential Therapeutics

Drug Profile

Research programme: MC 305904 anti-fungals - Essential Therapeutics

Alternative Names: MC 305904 antifungals research programme - Essential Therapeutics; Tubulin polymerisation inhibitors research programme - Essential Therapeutics

Latest Information Update: 04 Oct 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Essential Therapeutics [CEASED]
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 04 Oct 2004 Essential Therapeutics has closed down
  • 04 Oct 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
  • 09 Jan 2002 Preclinical development for Mycoses in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top